Abstracts tagged "Myositis"

Abstract Number: 1169 • ACR Convergence 2023
All-cause Mortality and Risk Factors for Death in a Large Multi-center Prospective Registry Cohort of Idiopathic Inflammatory Myositis in China
Liying Peng¹, Peng Yin², Mucong Li³, Qian Wang⁴, Yanhong wang¹, Shuang Zhou⁴, chanyuan wu⁴, Jiuliang zhao¹, Dong xu⁵, Mengtao Li³ and xiaofeng Zeng⁴, ¹Peking Union Medical College, Beijing, China, ²Chinese Center for Disease Control and Prevention, Beijing, China, ³Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ⁴Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ⁵Peking Union Medical College Hospital, Beijing, China
Background/Purpose: Our study depicted the mortality and independent risk factors of IIM patients in a large multi-center prospective registry cohort in China. Methods: Patients registered…
Abstract Number: 1927 • ACR Convergence 2023
Manifestations, Management and Outcomes of Interstitial Lung Disease Associated with Anti-synthetase Syndrome: A Systematic Literature Review
Koushan Kouranloo¹, Mrinalini Dey², Veronica Yioe³, Lisa G Spencer³ and Caroline V Cotton⁴, ¹Rheumatology & Internal Medicine Trainee- Surrey, UK. Education fellow University of Liverpool, Liverpool, United Kingdom, ²Queen Elizabeth Hospital, London, United Kingdom; University of Liverpool, Liverpool, United Kingdom, ³Liverpool Regional Lung Disease Service, Aintree Hospital, Lower Lane, Liverpool, United Kingdom, ⁴Department of rheumatology, Liverpool University NHS Foundation Trust, Liverpool, United Kingdom
Background/Purpose: Anti-synthetase syndrome (ASS) is a chronic autoimmune inflammatory condition, characterized by myositis, interstitial lung disease (ILD), arthritis, Raynaud's phenomenon and mechanic's hands. This systematic…
Abstract Number: 1965 • ACR Convergence 2023
Discordance Between Patient and Physician Perception of Disease Activity Among Patients with Idiopathic Inflammatory Myopathies: Results from the COVAD Study
Mrinalini Dey¹, Rudra Prosad Goswami², Parikshit Sen³, Samuel Shinjo⁴, Nelly Ziade⁵, Ioannis Parodis⁶, Mrudula Joshi⁷, Marcin Milchert⁸, Abraham Edgar Gracia-Ramos⁹, Lorenzo Cavagna¹⁰, Vishwesh Agarwal¹¹, Johannes Knitza¹², Jessica Day¹³, Hector Chinoy¹⁴, COVAD Study Group¹⁵, Vikas Agarwal¹⁶, Rohit Aggarwal¹⁷ and Latika Gupta¹⁸, ¹Queen Elizabeth Hospital, London, United Kingdom; University of Liverpool, Liverpool, United Kingdom, ²Department of Rheumatology, All India Institute of Medical Sciences, New Delhi, India, ³Maulana Azad Medical College, 2-Bahadurshah Zafar Marg, New Delhi, Delhi-110002, India., Dalhi, India, ⁴Faculdade de Medicina FMUSP, Universidade de Sao Paulo, São Paulo, Brazil, ⁵Saint-Joseph University, Beirut, Lebanon, ⁶Karolinska Institutet, Stockholm, Sweden, ⁷Byramjee Jeejeebhoy Government Medical College and Sassoon General Hospitals, Pune, India, ⁸Department of Internal Medicine, Rheumatology, Diabetology, Geriatrics and Clinical Immunology, Pomeranian Medical University in Szczecin, Szczecin, Poland, ⁹Department of Internal Medicine, General Hospital, National Medical Center "La Raza", Instituto Mexicano del Seguro Social, Av. Jacaranda S/N, Col. La Raza, Del. Azcapotzalco, C.P. 02990, Mexico City, Mexico, ¹⁰Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, ¹¹Mahatma Gandhi Missions Medical College, Lucknow, India, ¹²Department of Internal Medicine 3 Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, ¹³Walter and Eliza Hall Institute, Melbourne, Australia, ¹⁴The University of Manchester, Sale, United Kingdom, ¹⁵-, -, ¹⁶Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, ¹⁷University of Pittsburgh, Pittsburgh, PA, ¹⁸Royal Wolverhampton Trust, Wolverhampton/University of Manchester, United Kingdom
Background/Purpose: Disease activity assessment is key in the management of patients with idiopathic inflammatory myopathies (IIM). However, patients' perception of disease may differ from clinicians.…
Abstract Number: 2579 • ACR Convergence 2023
Validation of PROMIS in Adult and Pediatric Patients with Idiopathic Inflammatory Myopathies
Emma Austenfeld¹, Sara Sabbagh¹, Melodee Liegl¹, Ke Yan¹, Julie Fuller², Kelly Rouster-Stevens³, Lisa Rider⁴ and Adam Schiffenbauer⁴, ¹Medical College of Wisconsin, Wauwatosa, WI, ²UT Southwestern and Scottish Rite for Children, Dallas, TX, ³Emory University/Children's Healthcare of Atlanta, Norcross, GA, ⁴NIEHS, NIH, Bethesda, MD
Background/Purpose: This study aimed to validate the Patient Reported Outcome Measurement Information System (PROMIS) tools in patients with adult and juvenile idiopathic inflammatory myopathies (IIM/JIIM)…
Abstract Number: 0288 • ACR Convergence 2023
Proinflammatory Bioactive Lipid Mediators (BLM) Are Associated with Worse Anti-Oxidant Function of High Density Lipoproteins (HDL) in Patients with Idiopathic Inflammatory Myopathies (IIM)
Sangmee Bae¹, Ani Shahbazian¹, Jennifer Wang², Dawoud Sulaiman³, David Meriwether⁴, srinivasa Reddy⁵ and Christina Charles-Schoeman⁶, ¹UCLA Rheumatology, Los Angeles, CA, ²University of California Los Angeles, Los Angeles, CA, ³UCLA Cardiology, Los Angeles, CA, ⁴UCLA Digestive Diseases, Los Angeles, CA, ⁵UCLA Department of Molecular and Medical Pharmacology, Los Angeles, CA, ⁶UCLA Medical Center, Santa Monica, CA
Background/Purpose: Lipid oxidation products produced by artery wall cells under oxidative stress not only regulate immune responses, but their accumulation in HDL are shown to…
Abstract Number: 0748 • ACR Convergence 2023
Assessment of Myositis-related Interstitial Lung Disease by ⁶⁸ Ga-DATA.SA.FAPi PET/CT
Kastriot Kastrati¹, Thomas S Nakuz², Oana C Kulterer², Stephan Blüml³, Michael Bonelli³, Irina Gessl⁴, Hans-Peter Kiener³, Werner Langsteger², Daniel Mrak³, Florian Prayer⁵, Helmut Prosch⁵, Elisabeth Simader³, Tatjana Traub-Weidinger², Daniel Aletaha⁶, Helga Radner⁷, Marcus Hacker² and Peter Mandl³, ¹Dept of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna (Austria), Vienna, Austria, ²Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria, ³Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, ⁴Department of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁵Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria, ⁶Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria, Wien, Austria, ⁷Division of Rheumatology, Medical University of Vienna, Vienna, Austria
Background/Purpose: Interstitial lung disease (ILD) is a common manifestation of idiopathic inflammatory myopathies (IIM) ranging up to 78% in IIM and is a key contributor…
Abstract Number: 1170 • ACR Convergence 2023
Damage Accrual in Idiopathic Inflammatory Myopathies: Data from a Monocentric Cohort and Impact on Patients’ Quality of Life
Chiara Cardelli¹, Simone Barsotti², Elenia Laurino¹, Michele Diomedi¹, Federico Fattorini¹, Alessandra Tripoli¹, Linda Carli¹ and Marta Mosca¹, ¹Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ²Internal Medicine, Ospedale di Livorno, Pisa, Italy
Background/Purpose: Although the prognosis of Idiopathic Inflammatory Myopathies (IIMs) has noticeably improved over time, their chronicity may still expose a considerable number of patients to…
Abstract Number: 1945 • ACR Convergence 2023
Case Series of 6 Patients Exhibiting Myositis as a Rheumatologic Adverse Events Related to Cancer Immunotherapy in Two Spanish Hospitals
Arturo Llobell¹, Inigo Gonzalez-Mazon², carmen secada³, Adrian Martin-Gutierrez³, Almudena García-Castaño³, Enrique Gallardo⁴, Soledad Retamozo⁵, Antonio Gomez-Centeno⁶, Luis Fernandez-Morales⁴, Jordi Gratacos Masmitja⁷ and Ricardo Blanco⁸, ¹Parc Tauli University Hospital, Barcelona, Spain, ²Hospital Universitario Marques de Valdecilla, Santander, Spain, ³Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴Parc Taulí University Hospital, Sabadell, Spain, ⁵Laboratory of Autoimmune Diseases Josep Font, IDIBAPS-CELLEX, Barcelona, Spain, ⁶Parc Taulí Hospital Universitari, Sabadell, Spain, ⁷University Hospital Parc Taulí, Sabadell, Spain, ⁸Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Myositis is a rare inflammatory complication associated with immune related adverse events (irAE) of immune checkpoints inhibition (ICI) immunotherapy1. It is characterized by musculoskeletal…
Abstract Number: 1967 • ACR Convergence 2023
Infectious Myopathies in an Urban Inflammatory Idiopathic Myopathy Cohort: Frequency and Impact on Disease Course and Treatment
Ana Valle¹, Talia Meisel¹, Xianhong Xie² and Shereen Mahmood³, ¹Montefiore Medical Center, Bronx, NY, ²Albert Einstein College of Medicine, Bronx, NY, ³Albert Einstein College of Medicine / Montefiore Medical Center, New York, NY
Background/Purpose: Over the last few decades, it has been established that multiple infections can mimic idiopathic inflammatory myopathies (IIM). HIV, HTLV-1, and Lyme disease are…
Abstract Number: 0291 • ACR Convergence 2023
Myopathy Related to Small-to-medium-sized Vessel Vasculitis: Immunopathological Characteristics
Shun Nomura, Yasuhiro Shimojima, Takanori Ichikawa, Daigo Miyazaki, Dai Kishida and Yoshiki Sekijima, Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan
Background/Purpose: Muscular involvement develops as the initial manifestation of small-sized vessel vasculitis (SV) and medium-sized vessel vasculitis (MV).The musculoskeletal lesion has been found as a…
Abstract Number: 0783 • ACR Convergence 2023
Tolerability of CAR T Cell Therapy in Autoimmune Disease
Jule Taubmann¹, Fabian Müller², Michael Aigner³, Ioanna Minopoulou⁴, Johannes Knitza⁵, Dagmar Werner⁶, Christina Bergmann⁷, Gerhard Kroenke⁸, Andreas Mackensen³ and Georg Schett⁶, ¹Department of Internal Medicine 3, Rheumatology and Immunology, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität Erlangen Nürnberg, Erlangen, Germany, ²Friedrich Alexander Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ³Department of Internal Medicine 5, Hematology and Oncology, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität Erlangen Nürnberg, Erlangen, Germany, ⁴Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg & Universitätsklinikum Erlangen, Department of Internal Medicine 3 - Rheumatology and Immunology / Deutsches Zentrum Immuntherapie, Erlangen, Germany, ⁵Department of Internal Medicine 3 Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, ⁶FAU Erlangen-Nürnberg, Erlangen, Germany, ⁷Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, ⁸Charite Berlin, Berlin, Germany
Background/Purpose: We have previously shown that CD19 CAR T cell therapy can lead to improvement of severe forms of B cell mediated autoimmune disease including…
Abstract Number: 1171 • ACR Convergence 2023
Cardiac Biomarkers Are a Useful Initial Screening Tool for Myocarditis in Patients with Idiopathic Inflammatory Myopathies
Caoilfhionn M. Connolly¹, Jana Lovell², Melody Chung³, Brittany Adler², Jemima Albayda², Eleni Tiniakou², Christopher Mecoli¹, Stefan Zimmerman², Lisa Christopher-Stine², Nisha Gilotra² and Julie Paik², ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Kaiser Permanante, Baltimore, MD
Background/Purpose: Myocarditis in idiopathic inflammatory myopathies (IIM) is poorly understood despite its associated morbidity and mortality. As manifestations of myocarditis can be mild or subclinical…
Abstract Number: 1946 • ACR Convergence 2023
Zetomipzomib Demonstrates Favorable Long-term Safety and Tolerability Profile Without Signs of Immunosuppression: Results from the PRESIDIO Study and Its Open-label Extension Study in Patients with Dermatomyositis and Polymyositis
Rohit Aggarwal¹, Namita Goyal², Diana Lam³, Allen Ng³, Richard Leff⁴, Kathryn Ray³, Eunmi Park³ and Noreen Henig³, ¹University of Pittsburgh, Pittsburgh, PA, ²UCI Health, Orange, CA, ³Kezar Life Sciences, South San Francisco, CA, ⁴Kezar Life Sciences, Chadds Ford, PA
Background/Purpose: Polymyositis (PM) and dermatomyositis (DM) are chronic autoimmune diseases characterized by muscle inflammation and weakness. In a collagen-induced myositis mouse model, immunoproteasome inhibition has…
Abstract Number: 1968 • ACR Convergence 2023
Pregnancy Outcomes in Idiopathic Inflammatory Myopathies: A Comparison to the General American Population
Ana Valle¹, Melissa Fazzari² and Shereen Mahmood³, ¹Montefiore Medical Center, Bronx, NY, ²Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, ³Albert Einstein College of Medicine / Montefiore Medical Center, New York, NY
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are rare autoimmune conditions which cause multi-organ inflammation, particularly in the skin, lungs, and muscles. It is known that many…
Abstract Number: 0292 • ACR Convergence 2023
Comparison of Cardiovascular Risk of Myositis Patients and the General Population
Sabina Oreska¹, Hana Storkanova¹, Jaroslav Kudlicka², Vladimir Tuka², Ondrej Mikes², Zdislava Krupickova², Martin Satny², Eva Chytilova², Jan Kvasnicka², Maja Spiritovic³, Barbora Hermankova⁴, Petr Cesak⁵, Marian Rybar⁶, Karel Pavelka¹, Ladislav Senolt⁷, Herman Mann⁸, Jiri Vencovsky¹, Michal Vrablik² and Michal Tomcik¹, ¹Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ²3rd Department of Internal Medicine, General University Hospital and 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ³Institute of Rheumatology, Prague, Czech Republic, Department of Physiotherapy, Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, ⁴Department of Physiotherapy, Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, ⁵Department of Human Movement Laboratory, Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, ⁶Department of Biomedical Technology, Faculty of Biomedical Engineering, Czech Technical University in Prague, Kladno, Czech Republic, ⁷Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Praha, Czech Republic, ⁸Institute of Rheumatology, Praha 2, Czech Republic
Background/Purpose: Cardiovascular (CV) risk due to accelerated atherosclerosis and impaired metabolism can be increased in idiopathic inflammatory myopathies (IIM) on behalf of systemic inflammation, limited…

« Previous Page
1
…
7
8
9
10
11
…
28
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].